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Since the first successes with structure-based drug design 
using X-ray crystallography in the 1990s, a wide range 
of biophysical technologies have matured to become 
key components of drug discovery platforms within 
pharmaceutical companies and academic laboratories. 
Areas in which biophysical measurements have had a 
particular impact include: enabling drug discovery for 
more challenging targets, such as protein–protein inter-
actions1,2; identifying binding kinetics as a crucial factor 
for efficacy and selectivity3,4,5; and providing the foun-
dation for fragment-based drug discovery (FBDD)6–8. 
Such technologies have also enabled studies of the ther-
modynamics of drug binding9. Biophysical data provide 
an important complement to data on biochemical and 
cellular activity as well as aggregation, solubility and cell 
permeability10, which have traditionally formed the basis 
of hit and lead discovery, prioritization and optimiza-
tion. Taken together, these developments have enabled 
a more rational, rigorous problem-solving approach to 
the early phases of drug discovery.
The major reason for the rise of biophysical meth-
ods within drug discovery is the increased experience 
in knowing when and how to apply the plethora of 
methods to answer diverse questions across a breadth 
of biological targets. With the aim of helping to dis-
seminate this experience, in this Review we provide an 
overview of the current range, strengths and limitations 
of biophysical methods used in drug discovery, giving 
examples of when and how they can have an impact 
on drug discovery. We first summarize the main tech-
niques and their requirements, and we then describe 
the information that they can provide and the stages at 
which they can be applied in the drug discovery pro-
cess. We conclude with a discussion of the opportuni-
ties for new developments in biophysics — for example, 
methods that are able to operate in more authentic and 
physiologically complex settings (that is, in a cellular, 
tissue or organism setting), as is the trend for other 
assay technologies.
What are the techniques?
A range of biophysical techniques are currently used 
to analyse the binding of a compound to a target. The 
available technologies differ in the physical principle that 
underlies the detection of binding, throughput, infor-
mation content, sample requirements, sensitivity and 
robustness of the resulting data. TABLE 1 summarizes 
the techniques used most frequently in drug discovery, 
together with the characteristics of typical experiments, 
and FIG. 1 shows typical data obtained from the different 
methods described in TABLE 1. Given the large number 
of biophysical techniques, this Review is inevitably not 
able to comprehensively cover all existing or developing 
techniques, and so some techniques are not discussed in 
detail or not mentioned.
Two main biophysical techniques are currently used 
to investigate the structure of protein–ligand complexes. 
The most common technique is X-ray crystallogra-
phy, which can be used for proteins of any size. X-ray 
diffraction patterns of either protein–ligand co-crystals 
or apoprotein crystals soaked with a ligand are used to 
determine the structure of the complex at atomic resolu-
tion and derive the geometry and other details of protein– 
ligand interactions11. Nuclear magnetic resonance 
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Abstract | Over the past 25 years, biophysical technologies such as X‑ray crystallography, nuclear 
magnetic resonance spectroscopy, surface plasmon resonance spectroscopy and isothermal 
titration calorimetry have become key components of drug discovery platforms in many 
pharmaceutical companies and academic laboratories. There have been great improvements in 
the speed, sensitivity and range of possible measurements, providing high‑resolution mechanistic, 
kinetic, thermodynamic and structural information on compound–target interactions. This Review 
provides a framework to understand this evolution by describing the key biophysical methods, 
the information they can provide and the ways in which they can be applied at different stages 
of the drug discovery process. We also discuss the challenges for current technologies and future 
opportunities to use biophysical methods to solve drug discovery problems.
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Table 1 | Selection of established biophysical methods for analysis of protein–ligand interactions
Technique  
or method
Strengths Limitations Typical material 
requirements
Affinity 
range
Throughput 
per day*
Refs
X‑ray crystallography
Protein–
compound 
co‑crystallization 
or apoprotein 
crystal soaking
• Identification of 
binding site for 
establishment of 
modes of action
• Direct visualization 
at atomic resolution 
of target–ligand 
interactions for 
structural optimization 
of lead compounds
• Need for diffraction 
quality crystals suitable 
for ligand soaking or 
co‑crystallization
• Often requires access 
to large research 
infrastructures 
(synchrotrons)
• No quantitative affinity 
information
• ~2.5–5 nmol 
crystallizable protein (for 
example, 15 μl of protein 
solution at 5–10 mg per 
ml with a MM of~30 kDa) 
per 96‑well nanodrop 
crystallization plate
No lower limit 
to 1 M
100s 11
NMR
Ligand‑observed 
NMR
• Confirmation of ligand 
binding to unlabelled 
proteins of any size
• Integrity of ligand 
and protein in every 
experiment
• Considerably large 
amounts of protein 
required (typically tens of 
milligrams for screening)
• Limited derived 
structural information
• ~3–6 nmol protein 
per compound or 
cocktail tested for 
1H experiments (for 
example, 0.1–0.2 mg 
protein with a MM of 
~30 kDa)
• Amount of protein 
needed is ~10 times less 
for 19F experiments
• Competitor ligand to 
confirm specific binding
100 nM–10 mM 100s 12–14
Protein‑observed 
NMR
• Monitor protein 
integrity upon ligand 
binding
• Titration can reliably 
determine Kd
• Binding epitope 
resolved from pattern 
of perturbations
• Can determine 
structure if NMR 
spectrum is assigned
• A large amount of 
isotopically labelled 
protein is required
• Screening of large 
libraries is only possible 
in multiplexing mode 
(see REFS 142–144)
• Only suitable for small 
proteins (MM <40 kDa)
• Protein with a MM of 
<40 kDa
• ~30 nmol of an 
isotopically labelled 
protein per compound 
tested (for example, 
~1 mg protein with a MM 
of ~30 kDa)
100 nM–1 mM 100s 13, 
142–144
SPR
Microfluidic 
surface‑based 
biosensor 
(immobilized 
protein)
• Direct time‑resolved 
determination of 
interactions over 
a broad range of 
conditions
• High sensitivity allows 
analysis of fragments
• Requires immobilization 
of functional target 
with high stability 
over time and towards 
regeneration procedures
• Signals affected by 
solvent effects
• ~15 nmol protein (for 
example, ~0.5 mg with 
a MM of ~30 kDa) for 
assay development 
and screening of 2,000 
compounds
• Reference compounds 
for evaluation of protein 
functionality
1 nM–500 μM 100s 15–17
Microarray‑based 
biosensor with 
CCD camera 
detection 
(immobilized 
compound 
library)
• Very high sensitivity
• Ultra‑high throughput 
(12,000 fragment 
interactions in 
triplicates per day)
• Requires chemical 
modification of 
compounds to 
immobilize ligands 
through a covalent linker 
to a surface, preferably in 
different orientations
• Detergents are not 
tolerated
• ~100–150 nmol protein 
(for example, 3–5 mg 
with a MM of ~30 kDa) 
to screen 120,000 
compounds
• Reference compounds to 
assess binding specificity 
or to identify allosteric 
binders
No lower limit 
to 500 μM
10,000s 18,19
TSA
• DSF for 
monitoring of 
protein thermal 
unfolding with 
a fluorescent 
reporter ligand 
(typically using 
qPCR)
• Fast and robust assay 
development
• Functional knowledge 
of target not necessary
• Requires a fluorescent 
dye
• Artefacts occur owing to 
fluorescence quenching 
or aggregation
• Not suitable for 
disordered or 
hydrophobic proteins
• 80 pmol protein per 
analysis (40 μl at 2 μM)
• Ideally use a protein with 
intermediate Tm (<50 °C)
1 nM–100μM 1,000s 20,21
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Table 1 (cont.) | Selection of established biophysical methods for analysis of protein–ligand interactions
Technique  
or method
Strengths Limitations Typical material 
requirements
Affinity 
range
Throughput 
per day*
Refs
Microcalorimetry
ITC • Direct determination 
of thermodynamic 
parameters for a binary 
system
• Only useful for binding 
events with an enthalpic 
component
• Very high protein 
consumption, requires 
high solubility of titrated 
component
• ~6–60 nmol protein per 
titration (for example, 
0.2–2 mg with a MM 
of~30 kDa)
• Concentrations needed 
are ~10 times the 
estimated Kd (when Kd is 
unknown, a 10–100 μM 
concentration range is 
used)
1 nM–100 μM 10s 9,22,23
DSC • Determination of the 
effect of a ligand on 
the thermal stability of 
a protein
• Can be used to study 
ultra‑tight binding that 
cannot be measured by 
other methods
• Very high protein 
consumption
• ~1.5–30 nmol protein 
per scan (for example, 
~500 μl at 0.1–2 mg 
per ml with a MM 
of~30 kDa)
• A Kd measurement 
requires a series of 
scans at different 
concentrations
Dissociation 
constants 
down to 
10−20 M can be 
estimated
10s 23,145
MS
NC‑MS (also 
called native MS; 
usually ESI‑MS)
• Direct visualization  
of complex  
formation
• High sensitivity
• Very low protein 
consumption
• Accurate mass 
measurements
• High‑content 
information
• No labelling required
• Requires sample 
desalting
• Protein has to be 
stable in an ESI‑MS 
suitable buffer (usually 
a low‑concentration 
ammonium buffer)
• Detergents are not 
tolerated
• Unspecific binding 
makes the detection of 
low‑affinity binders more 
difficult
• 10–100 pmol protein per 
compound tested (2–5 μl 
at 5–20 μM)
No lower limit 
to 500 μM
100s 19,24, 
25
AS‑MS (also 
called SEC‑MS)
• Ultra‑high throughput 
when compound 
cocktails used
• Can be applied to 
solubilized membrane 
proteins
• Ligand mass detection 
enables verification of 
compound structure
• Low‑affinity binders 
(including fragments) 
are hard to detect 
because they tend to 
dissociate from the 
protein during the SEC 
step owing to high 
off‑rates
• 10 pmol protein (~2 μl at 
5 μM) per single‑binding 
reaction with a 
2,500‑compound library
No lower limit 
to 10 μM
1,000,000s 
(compound 
cocktails)
26
HDX‑MS • Direct detection of 
protein binding site 
and/or changes in 
protein conformation 
or protein dynamics 
upon binding
• Spatial resolution is 
limited and depends 
on peptide lengths 
and coverage of target 
sequence after protease 
cleavage
• ~30 nmol protein (for 
example, ~1 mg with a 
MM of ~30 kDa), mostly 
for assay development
No lower limit 
to 20 μM
10s 27,28
MST
Monitoring of 
changes in the 
thermophoretic 
motion of a 
fluorescently 
labelled or 
intrinsically 
fluorescent 
protein upon 
ligand binding
• In‑solution 
measurements
• Applicable to 
solubilized membrane 
proteins
• Requires labelling 
or strong intrinsic 
fluorescence
• Protein can either  
be fluorescently  
labelled or have 
detectable intrinsic 
fluorescence
• ~7 pmol protein per 
compound tested 
at 12 serial dilutions 
(twelve 10 μl aliquots 
of protein solution at 
60 nM) 
1 pM–1 mM 100s 29,30
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(NMR) spectroscopy can also be used to solve structures 
of protein–ligand complexes for targets with a molecular 
mass of less than ~40 kDa.
NMR also has a much wider application in probing 
ligand binding, through two alternative experimental 
setups: ligand-observed NMR and protein-observed 
NMR. In ligand-observed NMR, changes in the NMR 
parameters (mostly chemical shifts, relaxation rates and 
diffusion rates) of molecules or cocktails of molecules are 
measured in the presence of a target protein12–14. Typical 
experiments performed include magnetization trans-
fer experiments (saturation transfer difference (STD) 
NMR, water-ligand observed via gradient spectroscopy 
(waterLOGSY), transferred nuclear Overhauser effect 
(NOE), NOE pumping and other NOE-based methods), 
relaxation editing (longitudinal, transverse and double- 
quantum relaxation) and diffusion editing. The infor-
mation that can be obtained can range from simply 
determining whether the ligand interacts with a protein 
or not, to binding specificity and information on the 
binding mode (such as epitope mapping, pharmacophore 
mapping and mapping of ligand orientation). With some 
techniques it is possible to estimate binding affinities. 
In protein-observed NMR, the chemical shift pertur-
bations in the 2D NMR spectra of isotopically labelled 
proteins are monitored in the presence of ligands13. 
Such measurements are limited to small proteins (prac-
tically, those with a molecular mass <40 kDa), but when 
resonances have been assigned, the binding epitope and 
the dissociation constant (Kd) can be inferred from the 
data. Both methods require relatively large amounts of a 
protein, which needs to be stable and of high purity.
Surface plasmon resonance (SPR) is a spectroscopic 
technique that monitors changes in refractive index at 
the interface of a liquid sample and a surface with an 
immobilized sensor molecule, typically the target pro-
tein15–17. The signal is shifted as a result of analyte binding 
or induced conformational changes. When using micro-
fluidic systems with continuous registration of the signal, 
it is possible to characterize the binding mechanism and 
Table 1 (cont.) | Selection of established biophysical methods for analysis of protein–ligand interactions
Technique  
or method
Strengths Limitations Typical material 
requirements
Affinity 
range
Throughput 
per day*
Refs
SAXS
Low‑angle elastic 
scattering of 
X‑rays, bringing 
information 
about the shape 
and size of 
macromolecules
• Larger‑scale structural 
changes of proteins 
upon ligand binding 
can be visualized at low 
resolution with high 
throughput
• Low resolution (1–2nm) 
does not allow for 
elucidation of atomic 
details of ligand 
interactions
• Monodisperse protein 
material
• ~1 nmol protein per 
sample (for example, 
~0.03 mg with a MM of 
~30 kDa)
• ~100 nmol protein for an 
entire study (for example, 
~3 mg with a MM of 
~30 kDa)
• Typically, a concentration 
series is measured 
for each sample (for 
example, 1, 2, 5 and 
10 mg per ml)
No lower limit 
to 30 μM
100s 31,32
QCM
Monitoring of 
the vibration 
frequency of a 
quartz crystal 
upon interaction 
between an 
analyte and an 
immobilized 
protein or cell
• Direct time‑resolved 
determination of 
interactions with 
proteins and cells
• Requires immobilization 
of functional target with 
high stability over time 
and robustness towards 
regeneration procedures
• ~15 nmol protein (for 
example, ~0.5 mg with 
a MM of ~30 kDa) for 
assay development and 
screening campaign
1 nM–500 μM 100s 33,34
Rotating cell‑based ligand binding assay using radioactivity or fluorescence
Monitoring 
of molecular 
interactions 
at the surface 
of cells using 
radioactivity or 
fluorescence
• Direct time‑resolved 
determination of 
interactions between 
labelled ligands with 
surface‑associated 
proteins
• Laboratory requirement 
to work with radioactivity 
(not with fluorescent 
compounds)
• ~105 cells per assay
• Fluorescent or 
radioactively 
labelled analytes (in 
approximately picomolar 
amounts)
1 pM–1 μM 10s 35
AS‑MS, affinity selection mass spectrometry; CCD, charge‑coupled device; DSC, differential scanning calorimetry; DSF, differential scanning fluorimetry; ESI‑MS, 
electrospray ionization mass spectrometry; HDX‑MS, hydrogen–deuterium exchange mass spectrometry; ITC, isothermal titration calorimetry; MM, molecular 
mass; MS, mass spectrometry; MST, microscale thermophoresis; NC‑MS, non‑covalent mass spectrometry; NMR, nuclear magnetic resonance; qPCR, quantitative 
PCR; QCM, quartz crystal microbalance; SAXS, small‑angle X‑ray scattering; SEC‑MS, size‑exclusion chromatography mass spectrometry; SPR, surface plasmon 
resonance; Tm, transition midpoint for thermal unfolding; TSA, thermal shift analysis. *Number of protein‑ligand experiments per day for a well‑behaved system 
with optimal facilities.
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determine the corresponding kinetic parameters (the 
association rate constant (kon) and the dissociation rate 
constant (koff)) and the affinity (Kd). Thermodynamic 
parameters can also be estimated by performing analyses 
at multiple temperatures. An alternative configuration of 
SPR involves imaging of a microarray with immobilized 
small-molecule sensors using a charge-coupled device 
(CCD) camera, providing information on binding (yes 
or no) and binding specificity through on-array com-
petition experiments18,19. Both of these SPR techniques 
require immobilization of one of the binding partners, 
either the protein in the microfluidic system or a ligand 
library in the microarray technology. In the latter case, 
the protein is in the solution over the microarray, and 
thus, as the signal depends on the mass of the analyte 
(in this case, the protein), the detection of binding in this 
setup is extremely sensitive.
Thermal shift analysis (TSA), also known as differ-
ential scanning fluorimetry (DSF), measures the tem-
perature at which a protein unfolds through binding of 
a fluorescent probe to the exposed hydrophobic sur-
faces20,21. If a ligand stabilizes or (less frequently) desta-
bilizes the fold upon binding, then there will be a change 
in the transition midpoint for thermal unfolding (Tm) 
(positive or negative, respectively). In some cases, it is 
also possible to determine Kd values. The major advan-
tages of the method are its fast set up, its inexpensiveness 
and the requirement of only small amounts of protein 
material.
Two major microcalorimetry techniques are used for 
studying protein–ligand interactions9,22,23. Isothermal 
titration calorimetry (ITC) measures the generation or 
consumption of heat following titration of a ligand on 
to a protein (or the reverse). The data obtained include 
stoichiometry, Kd, change in enthalpy (ΔH), change 
in entropy (ΔS) and the heat capacity change (ΔCP). 
Differential scanning calorimetry (DSC) measures heat 
changes (and corresponding thermodynamics) resulting 
from the thermal unfolding of a protein. An advantage 
of these techniques is that experiments are performed 
in solution, but large amounts of protein are typically 
required.
Mass spectrometry (MS) is also used in different 
modes. Non-covalent MS (NC-MS), also called native 
MS, is usually carried out using electrospray ioniza-
tion MS (ESI-MS), generating data that can confirm 
binding, assess specificity through competition exper-
iments, define stoichiometry, measure Kd and give an 
estimate of the enthalpic component of binding19,24,25. 
Affinity-selection MS (AS-MS), also called size-exclusion 
chromatography MS (SEC-MS), can be used to study 
protein–ligand interactions26, but with decreased infor-
mation content. Typically, a protein is incubated with a 
library of compounds and passed through a SEC column 
to isolate any compounds that are bound to the protein 
and therefore coelute with the protein. The protein com-
plexes are then dissociated and the ligands are identified 
by LC-MS or ESI-MS. In this case, confirmation of bind-
ing and Kd values can be obtained. Finally, hydrogen– 
deuterium exchange MS (HDX-MS) can be used to 
measure the altered accessibility to deuterium exchange 
of amino acids involved in ligand binding. This method 
has successfully been used for the characterization of 
protein–protein interactions, such as those between 
epitope binding regions of therapeutic antibodies 
and their antigens. Furthermore, small-molecule 
binding and alterations in protein dynamics can be 
investigated27,28. The method works for soluble and 
membrane-bound proteins and relies on an appropriate 
protease cleavage pattern to get accurate sequence 
coverage.
Microscale thermophoresis (MST) is a relatively new 
methodology that monitors fluorescence in an infrared 
laser-heated spot. It is an equilibrium-based method 
that can detect ligand binding-induced changes in 
thermophoretic mobility (the motion of protein mole-
cules along a microscopic temperature gradient), which 
depend on size, charge and hydration shell29,30. These 
changes in thermophoretic mobility can be used to 
estimate Kd values.
Small-angle X-ray scattering (SAXS) can be used to 
study protein–protein, protein–DNA, protein–RNA and 
protein–small molecule interactions in solution, provid-
ing information on the folding, oligomerization state and 
intrinsic flexibility of a protein and its complexes, as well 
as the shape of an assembly and an envelope structure 
to a 1–2-nm resolution31,32. Although we are not aware 
of any extensive ligand screening efforts, SAXS can be 
used to monitor the effect of ligands on the modulation 
of protein–protein interactions and of the conformation 
and oligomeric state of intrinsically disordered proteins.
Quartz crystal microbalance is a continuous flow sur-
face biosensor that measures changes in the vibration 
frequency of a quartz crystal following an interaction 
between an analyte and an immobilized target protein or 
cell, quantified as Kd, kon, koff or thermodynamic param-
eters33,34. Finally, the rotating cell-based ligand binding 
assay is a relatively new method for real-time monitoring 
of molecular interactions on cells using radioactivity or 
fluorescence35. This method provides data that can be 
used to characterize the binding mechanism, as well as 
Kd, kon and koff.
What do these techniques require?
All of these techniques have certain requirements for 
the compound to be tested. Ideally, the compound must 
be soluble well above its binding affinity constant, stable 
and non-aggregating under the given experimental 
conditions. However, even under the same experimen-
tal conditions, different techniques demand different 
levels of solubility relative to affinity. For instance, in 
ligand-observed NMR, a low occupancy of the protein 
binding site by the ligand (<20%) suffices to observe 
binding, whereas in X-ray crystallography a substantial 
percentage (>50%) of binding sites must be occupied 
to unambiguously identify binding and resolve the 
protein–ligand co-structure.
Similarly, for a robust measurement, all of the tech-
niques require the protein target to be homogenous and 
well behaved at relatively high concentrations. However, 
each of the techniques has differing requirements for the 
amount, characteristics and preparation of the target. 
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Figure 1 | Typical data obtained from biophysical methods in drug 
discovery. Visual representation of data obtained from methods in 
TABLE 1. a | Detail of an electron density map derived from X‑ray 
diffraction data for a fragment binding to the amino terminus of 
heat‑shock protein 90 (HSP90). b | A small portion of a 2D 1H–15N 
heteronuclear single quantum coherence nuclear magnetic resonance 
spectrum (protein‑observed mode). Resonances in the absence and 
presence of ligand are coloured blue and red, respectively. c | A typical 
channel‑based surface plasmon resonance (SPR) sensorgram at different 
analyte concentrations. d | A fingerprint from a microarray SPR screening, 
showing the SPR shift on a relative colour scale. The horizontal and 
vertical axes correspond to the x and y coordinates on the microarray. 
Fragment hits are easily identified from triplicate patterns. e | A typical 
recording of relative fluorescence intensity versus temperature for the 
unfolding of a protein target in the presence of a fluorescent dye. The blue 
and red curves are the recordings in the absence and presence of test 
compound, respectively. In the depicted case, the test compound 
stabilizes the protein (change in transition midpoint for thermal unfolding 
(ΔTm) >0). f | A thermogram showing heat absorption rates (microjoules 
per second) upon sequential ligand additions to a target solution 
(isothermal titration calorimetry; ITC) (raw data). g | A portion of a native 
mass spectrum. Upon ligand addition, the peaks corresponding to the 
apoprotein decrease and the peaks corresponding to the protein–ligand 
complex increase. The mass difference can be used to evaluate the 
binding stoichiometry. h | The deuteration level (observed deuterium 
uptake over the maximum theoretical uptake) for each peptide at 
increasing time points (from top to bottom) in the absence and presence 
of a ligand. i | Fluorescence monitoring of the thermophoretic motion of 
a target at different ligand concentrations. j | Small‑angle X‑ray 
scattering curves for a protein–protein complex at different 
concentrations. k | Typical quartz crystal microbalance (QCM) sensorgram 
at different analyte concentrations. l | Relative intensity versus time 
showing the interaction of a fluorescent antibody with receptors at the 
surface of living cells. The red and blue curves depict two independent 
experiments. Δm/z, change in mass‑to‑charge ratio; MST, microscale 
thermophoresis; ppm, parts per million.
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Clearly, X-ray crystallography requires crystals, which 
usually means at least a few milligrams of protein at 
more than 10 mg per ml concentration. Advances such 
as cryocooling, microfocus beamlines and new detec-
tor technologies have dramatically reduced the number 
of crystals required to determine 3D structures. New 
developments — such as serial crystallography done at 
room temperature in combination with the ultra-high 
brilliance of X-rays from free-electron lasers — have 
the potential to work with crystals of sub-micrometre 
dimension. For NMR, improved electronics and the 
advent of cryogenic probes have increased sensitivity by 
more than tenfold over the past 10 years, reducing either 
the amount of sample required or the measurement time; 
nevertheless, a protein solubility of around 10 μM or 
greater is still required. Ligand-observed NMR measure-
ments can be made on unlabelled targets of any molec-
ular mass, whereas protein-observed NMR is mostly 
limited to proteins of less than 40 kDa and requires 
isotope labelling (one or more of 15N, 13C and 2H). 
Routine labelling is only possible by overproduction in 
engineered bacterial cell lines; the recent innovation of 
selective labelling of specific amino acid types has made 
it possible to exceed the 40 kDa limit of protein-ob-
served NMR. Improvements in label-free native ESI-MS 
have led to greater throughput and the ability to screen 
hundreds of compounds while still allowing the detailed 
characterization of the interaction25.
There is a growing collection of methods in which 
either the target or the compound is ‘tethered’ to some 
aspect of the instrument such that the binding of the 
other ‘free’ component can be characterized. The different 
methods, such as SPR, bio-layer interferometry (BLI) and 
weak affinity chromatography (WAC), have the common 
advantage of allowing the binding of many compounds 
to be measured if a small quantity (less than 1 mg) of the 
target can be tethered without disturbing target folding, 
ligand binding properties or function. Such methods are 
also prone to similar artefacts, such as nonspecific inter-
action of compounds with the immobilization medium 
and the possible influence of additives or co-solvents 
(for example, DMSO) on the binding signals. The assay 
sensitivity of larger target proteins can be compromised 
if steric constraints limit the amount that can be tethered, 
and the binding of small ‘free’ ligands can lead to small 
signals when the technique relies on changes in mass or 
refractive index close to the sensor surface. This is a class 
of techniques for which increased experience and educa-
tion has greatly improved application36,37, and there is now 
widespread understanding and acceptance of the stringent 
controls needed to validate the experimental protocol.
The thermal techniques (TSA, ITC and DSC) are all 
solution-based and do not require immobilization of 
either the target or ligand. The artefacts in TSA meas-
urements are well documented38, but TSA benefits from 
ease of use and requires only micrograms of material. 
ITC is the gold standard for direct binding measure-
ments. Unfortunately, despite substantial improvements 
in calorimeter instrument sensitivity, milligrams of pro-
tein and high compound solubility are still required to 
characterize the binding of each compound.
Finally, there are a number of techniques that rely on 
fluorescence (either intrinsic or extrinsic) of either the 
target or the compound, such as MST and fluorescence 
polarization (FP). These solution-based methods bring 
additional considerations and a need for validation steps 
if extrinsic labelling is used, as the fluorophore itself may 
affect some aspect of the binding.
What information can currently be obtained?
One of the challenges for drug discovery researchers 
who are not familiar with biophysical techniques is to 
understand what type of questions can be addressed by 
such techniques and which techniques are the most suit-
able. The following discussion provides some examples 
of ‘typical’ questions posed and the techniques that are 
currently routinely and robustly used in our laboratories. 
The discussion uses the phrase ‘tool compound’ to repre-
sent a compound that is known to bind with a particular 
affinity to a specific site on the target, and is soluble, 
stable and non-aggregated under the conditions used to 
make measurements.
Is the target folded? A 1D proton NMR spectrum of an 
unlabelled protein is relatively quick to obtain. A folded 
protein will have narrow peaks spread over a large chem-
ical shift range (–0.5 to +10.5 ppm), often with distinct 
peaks at the extremes of the distribution. An unfolded 
or partially folded protein will have broader and less 
well-dispersed peaks, often close to their random chem-
ical shift values. Similarly, a circular dichroism spectrum 
will reflect folding, particularly for proteins containing 
substantial numbers of α-helices. A more rapid way of 
characterizing protein samples is by TSA, through which 
a clear thermal melt curve is a quick way to characterize 
folding and homogeneity across samples, particularly if 
a tool compound is available.
Does a compound bind to the target? All of the tech-
niques in TABLE 1 can be configured to detect the binding 
of a compound to the target, with the dynamic ranges 
indicated. Some techniques provide more information 
than others (as discussed here), but all provide the essen-
tial first assessment of whether the compound binds or 
not — with real confidence if a tool compound is availa-
ble for assay validation. Measurements at different ligand 
concentrations and evaluation of dependence on concen-
tration provide additional information on the binding 
behaviour and an estimation of the affinity.
What is the stoichiometry of binding? Accurate stoi-
chiometry measurements are difficult, as they require 
accurate knowledge of both the total ligand and mac-
romolecule concentrations and the fraction that is able 
to form a complex. The absolute errors need to be less 
than 20% on each of these to be able to confidently dis-
tinguish a 1:1 from a 2:1 complex. ITC is probably the 
most routinely used method to determine stoichiometry, 
but it consumes large quantities of protein. SPR is a good 
alternative when a suitable tool compound is available. 
Single-molecule methods would avoid the need for pre-
cise concentration determination and may overcome 
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sample consumption issues. Currently, the closest tech-
nique that matches this is NC-MS, which has many 
attributes that make it a valuable biophysical technique 
for drug discovery24,25. However, further development of 
the method is required for more routine use39.
Where does the compound bind? In the absence of an 
X-ray structure of the ligand complex, the most robust 
technique for identifying where a compound binds is 
heteronuclear single quantum coherence (HSQC) NMR 
spectroscopy (usually 15N but sometimes 13C). Each peak 
in the spectrum reports on the local chemical environ-
ment of the resonant nuclei, which can be altered by 
compound binding. If the spectrum is assigned, such that 
peaks can be linked to individual protein residues, then 
the actual site of binding can be identified; if not, then a 
fingerprint of peak movements can determine whether 
compounds are likely to bind to the same site or dif-
ferent sites. Once a tool compound for a site has been 
identified, many types of competition displacement 
assay can be configured using other techniques to more 
rapidly test and characterize new compounds. However, 
it is important to remember that these displacement 
techniques do not directly report the site of binding, 
unlike NMR and X-ray crystallography, and allosteric 
site binders may displace probe compounds owing to 
long-range conformational effects. In any case, the use 
of site-specific mutants of the target can help to provide 
information about binding site location.
What is the atomic structure of the target–compound 
complex? X-ray crystallography is the most powerful, 
robust and routine method for providing a detailed atomic 
picture of a compound binding to its target. There are rare 
examples of discrepant observations between soaked and 
co-crystallized complexes (for example, when targets 
require conformational change or when crystal packing 
interferes with ligand binding) or when the crystalliza-
tion conditions themselves affect the ligand binding mode 
(for example, pH). Therefore, as with other experimental 
methodologies, corroborating data from X-ray structures 
obtained by alternative crystallization protocols or from 
orthogonal solution studies such as NMR provide a more 
complete picture.
What are the thermodynamics of compound bind‑
ing? ITC is the most direct method used to measure 
the thermodynamic parameters of binding (Kd, ΔH 
and ΔS) and, with variation of temperature, ΔCP. The 
most straightforward and routinely used experiment is 
a direct binding titration, in which the heat change upon 
binding (ΔH) is monitored as small aliquots of a concen-
trated compound solution are injected into a solution 
containing the target at constant temperature. This con-
figuration can be reversed when the compound is less 
soluble and the protein target is highly soluble. Affinity 
measurements, most often using SPR, at different tem-
peratures can provide an alternative way of determining 
thermodynamic parameters using a van’t Hoff analysis 
(see below). However, this method involves additional 
assumptions and has not been widely used so far.
What are the kinetics of compound binding? SPR biosen-
sors with a microfluidic flow system and dextran surfaces 
are the most extensively used instruments for measuring 
ligand binding kinetics. With an appropriate configura-
tion, kon and koff can be determined by simply fitting an 
equation corresponding to a suitable model to the sen-
sorgram that results from the SPR experiment. Kd can also 
be derived as the ratio of koff to kon. For more complex 
interaction mechanisms, other kinetic parameters can 
be estimated. Many compounds have a relatively high kon 
(limited by the rate of diffusion) with an increasingly low 
koff as the affinity for the target increases. There is grow-
ing evidence from the literature demonstrating that ligand 
binding kinetics can influence efficacy and safety and 
therefore therapeutic success for some targets5. Attempts 
to increase our understanding of how to modulate these 
kinetics parameters by correlating them with X-ray ligand 
complexes to give structure–kinetic relationships (SKRs) 
are an area of great interest (see below for current status).
Where are biophysical techniques applied? 
Two major developments in drug discovery have been 
synergistic with the deployment of a wide range of 
sensitive biophysical methods: the increased focus on 
drug-like properties during compound optimization10 
and the rise of FBDD40. We begin with a brief overview 
of biophysical methods in FBDD, as this has driven and 
challenged the development of methods more than any 
other application in recent years. We then outline how 
these advances have been exploited in areas such as 
high-throughput screening (HTS), hit confirmation and 
more detailed characterization of compound binding.
Fragment screening. The first published example of FBDD 
was 20 years ago, with the seminal work of the Abbott 
group, which demonstrated that nanomolar affinity drug 
candidates could be derived from small fragments that 
bound with a millimolar Kd41,42. This group not only pio-
neered the use of protein-observed NMR experiments to 
detect weak interactors but also were the first to conduct 
fragment screening by crystallography43. Since then, many 
companies have been founded using fragment-based 
screening (FBS) as their primary hit identification 
strategy. Several of these are renowned for advancing 
methodologies for their chosen biophysical approach: 
for example, X-ray crystallography44,45, ligand-observed 
NMR spectroscopy46, SPR47, small-molecule microarray 
SPR18,19 and NC-MS19,25. In both large and small com-
panies, multiple established methods and increasingly 
emerging biophysical techniques (for example, MST and 
WAC)48 are applied concurrently during FBS hit valida-
tion. Comparisons of the range of FBS methods, including 
illustrative successful fragment-to-lead case studies, are 
well documented in literature reviews40. However, faced 
with a growing array of biophysical methods capable of 
FBS, two related questions are often posed and debated: 
why do different techniques result in different hit lists, and 
which is the ‘best’ FBS technique to use?
Although many studies report different hits depend-
ing on the screening method49, much of this discrepancy 
can be explained by variations in assay protocol and 
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detection method. Techniques have differential sensi-
tivity to the properties of individual compounds within 
the fragment library (for example, solubility, aggrega-
tion potential, stability and ability to interfere with the 
assay) and assay conditions used (for example, the effect 
of buffer conditions, including temperature and pH, 
on both the fragments and the targets). Consequently, 
weak-affinity fragments may lie just above or below 
an assay detection threshold as the balance of factors 
changes.
The goal of FBS is to detect the binding of low- 
molecular-mass compounds (typically <300 Da) with 
low affinity to a protein target (in the micromolar to 
millimolar range). It is widely acknowledged that there 
is no single ‘best’ technique; instead, the choice of tech-
nique, or often techniques, for primary FBS is frequently 
dictated by logistical and practical considerations such 
as equipment and protein availability. More importantly, 
we believe that success in FBS depends strongly on users’ 
experience and expertise, specifically the ability to estab-
lish robust assays, stringent data interpretation proto-
cols and a well-considered screening cascade. In some 
instances, an inclusive strategy is adopted, progressing all 
hits from all of the applied methods; in others, only over-
lapping hits validated by more than one technique are 
included. Both strategies can be appropriate depending 
on the circumstances and when they are chosen in light 
of an understanding of the acquired FBS knowledge, 
discussed in BOX 1.
The adoption of FBDD in some organizations has 
required changes in the processes and gate-keeping 
criteria for progression through early drug discovery. 
Fragments straight out of FBS often have no measur-
able target function (either agonism or antagonism). 
Therefore, it is important to develop robust models of 
how fragments bind and to understand the opportunities 
and probability for successful affinity optimization. After 
the initial investment to improve affinity independently 
of activity, for fragments that register detectable func-
tional activity, conventional activity coupled with ligand 
efficacy criteria can be used to prioritize further chemis-
try efforts towards generating lead molecules. Another 
barrier is that many larger companies use multiple 
hit-finding strategies, so it can be difficult to persuade 
a medicinal chemistry team to undertake the optimi-
zation of a 500 μM fragment if a 100 nM hit is available 
from HTS. For these reasons, structural information on 
fragment–target complexes, usually obtained by X-ray 
crystallography, is considered essential in FBDD to pro-
vide insight into chemical opportunities for efficient 
fragment evolution50.
Most fragment screens are configured to identify 
compounds that bind to known binding sites (usually the 
active site of an enzyme). It is often straightforward to 
find many fragment hits for such ‘conventional’ targets, 
provided that the target protein can be readily generated 
and, in particular, that tool compounds are available to 
validate the various assays. For other target classes, inno-
vative experimental design may be required to identify 
and successfully develop these hits. The first example 
of a difficult target class is represented by proteins with 
druggable allosteric sites (often initially unknown and 
without a natural biological function). For this class, 
there are some striking examples in which careful design 
of NMR experiments has enabled: detection of hits that 
inhibit BCR–ABL kinase at a myristoyl binding site51; 
generation of non-bisphosphonate farnesyl pyrophos-
phate synthase inhibitors52; and discovery of compounds 
that activate enzymes such as glycoside hydrolase53. The 
second example of a difficult target class includes pro-
teins that transiently interact with other proteins or that 
form multi-protein complexes — two different types of 
important protein–protein interactions. For such systems, 
thorough experimental design and assessment with many 
orthogonal biophysical techniques is needed to validate 
fragment binding (for instance, see Winter et al.54).
HTS. Here, HTS is defined as screening a collection of 
~1 million compounds or more against a protein target 
to identify a compound subset that shows activity. Such 
screens are typically based on biochemical or cellular 
assays, often with optical detection. Few biophysical 
methods satisfy the throughput requirements of HTS55, 
although many are used at the secondary hit-validation 
stage56,57. TSA58 and, to some extent, MS59 are techniques 
that can be configured to provide the throughput, ease 
of access and low sample consumption needed for HTS 
screening. Cocktails of compounds are often used to 
reduce the number of measurements, material consump-
tion and costs. TSA was initially used for proteins of 
unknown function or when obtaining reagents required 
to establish a traditional biochemical displacement or 
enzymatic assay proved challenging. The simple format 
of TSA has facilitated its application to other protein 
classes, especially within academic laboratories.
Hit confirmation and validation. Biophysical methods 
are now routinely incorporated as an integral component 
of the HTS hit validation and characterization process 
of most pharmaceutical companies.
In the past, many HTS triage strategies relied solely 
on hits progressing through a series of negative selection 
assays designed to filter out compounds acting through 
unwanted effects, such as pan-assay interference com-
pounds (PAINS)60 — for example, compounds that cause 
target oxidation through their intrinsic redox activity, 
unstable or reactive compounds and compounds that 
induce protein aggregation. Unfortunately, this filtering 
approach is imperfect as not all nuisance mechanisms 
are known, and problematic compounds for some targets 
may be true high-quality ligands for others, as evidenced 
by the finding that 10% of a set of known drugs can 
exhibit ‘promiscuous’ activity61. This proves especially 
difficult for challenging targets such as protein–protein 
interactions, for which the number of authentic hits is 
often very low.
The use of positive selection assays provides an effec-
tive and efficient alternative approach, and many bio-
physical methodologies have been adopted to serve this 
purpose56,62. The major roles and benefits of biophysical 
approaches within hit validation fall into three catego-
ries. First, some approaches can allow the orthogonal 
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Target
confirmation of functional activity. For example, many 
screening assays use optical readouts such as fluores-
cence and luminescence to confirm activity. For enzyme 
assays, non-optical detection using RapidFire MS or 
NMR provides alternative ways to monitor substrate 
consumption or product build-up. The second major 
type of positive selection assays is those that verify direct 
target engagement. For example, a simple biophysical 
Box 1 | Observations from fragment-based screening studies 
After ~15 years of broadly applying the paradigm of fragment-based drug discovery (FBDD), accumulated experience in 
the industry has led to a common notion of best practices that are summarized here and illustrated in the figure.
X‑ray crystallography. An X-ray co-crystal structure of a target-bound fragment is considered the ultimate validation of the 
binding event. Therefore, screening by X-ray crystallography has the advantage that details of the fragment-binding mode 
are immediately available. Although the method has long been hampered by the relatively low throughput and high 
investments, access to synchrotron beamlines and automation in many process steps has substantially lowered the barriers 
for screening larger libraries. The disadvantages of this technique are that the protein crystal system has to be robust to 
soaking of ligands at a high concentration and must have solvent channels that allow fragments to easily penetrate the 
crystal and access the binding site. Success is governed as much by kinetics as by thermodynamics. Often, multiple soaking 
attempts are needed to obtain a structure of a true ligand to the protein, implying that screening by X-ray crystallography 
will result in many false negatives40.
Nuclear magnetic resonance spectroscopy. Nuclear magnetic resonance (NMR) spectroscopy is the most robust method for 
detecting very weak binding (micromolar affinity), with the added advantage that the spectra obtained report on the 
integrity of both the target (protein-observed NMR) or the ligand (ligand-observed NMR) with each assay step. Its main 
limitation is the amount of protein required — typically tens of milligrams for screening a 1,000-member fragment library.
Surface plasmon resonance. Surface plasmon resonance (SPR) provides a robust platform for screening and compound 
optimization37 and is one of the most widely used biophysical techniques in fragment-based screening. The main 
challenges for SPR are retaining full protein functionality after immobilization on a sensor chip, as well as the expertise and 
experience required to set up a high-quality assay and analysis protocol. The number of successful FBDD lead-generation 
projects using SPR as one of the main primary screening methods is steadily growing115,133–135. New instrumentation and 
adaptive strategies have led to a broadening of SPR technology applications to difficult target classes, such as 
membrane-bound proteins, for which novel reconstitution and tethering methods preserve the conformation and activity 
of the surface-bound protein115,133,135.
Thermal‑shift analysis. Thermal-shift analysis (TSA) methods are particularly attractive to academic groups, given the ease 
of instrument access. However, the degree of thermal stabilization upon fragment binding to a protein may be too small to 
be measured, and contaminants or counter ions co-present in samples can be sufficient to cause a thermal shift. In addition, 
this method can be a source of many false-positive and false-negative hits38,40.
Isothermal titration calorimetry. There are only a few examples in the literature using isothermal titration calorimetry (ITC) 
as a primary assay in fragment-screening campaigns, as this method has a very low throughput and equilibrium 
dissociation constants of fragment interactions are often too weak to be well determined22,127,136.
Fluorescence‑based assays. High-concentration screening using biochemical, often fluorescence-based, binding and 
functional assays has been reported for fragment screening40. The need for a fluorescent readout can result in more 
complex assay configurations — for example, the introduction of extrinsic fluorophores, coupling systems, antibodies and 
lanthanide reagents. This complexity increases the probability that, at the high compound concentrations used (typically 
~0.5–1mM), one or more of the assay components may be optically or physically perturbed by compound interference.
Orthogonal methods. Given the limitations of individual biophysical methods in identifying a set of bona fide binding 
fragments, validation of hits by orthogonal methods is now commonly applied. This can be done by running multiple 
biophysical assays on the entire fragment-screening library or by choosing a consecutive assay funnel format (highest 
sensitivity and throughput assays are run first).
Hit optimization without structural information. FBDD campaigns based on X-ray co-structures still represent the process 
gold standard. However, as initial biophysically identified fragment hits may turn out to be X-ray false negatives, and 
sometimes a few rounds of fragment optimization are needed to obtain a favourable ratio of affinity and solubility, 
researchers are now more encouraged to tackle targets lacking available structural information (termed ‘non-structurally 
enabled targets’) and prosecute FBS hits using classical medicinal chemistry strategies.
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binding experiment using SPR, NMR, NC-MS or MST 
can confirm that hits bind directly to the protein target 
of interest rather than to any other biochemical assay 
component, such as capturing antibodies or coupling 
enzymes. Third, positive selection assays can be used to 
determine whether the mode of action of a compound 
on a target protein is aligned with the biological under-
standing of the disease mechanism. This relies on the 
protein used in the assays being in a functionally rele-
vant state (for example, with regard to post-translational 
modification and binding partners). Briefly, biophysi-
cal assays can yield information on binding specificity 
and stoichiometry, and ITC and SPR provide additional 
quantitative data on binding thermodynamics and kinet-
ics that implicitly carry information on the mode of 
action of the hits (see below). X-ray crystallography (and 
NMR) can identify the ligand binding site on the target 
and elucidate the atomic details of the protein–ligand 
interactions. Taken together, these methods provide a 
comprehensive data package that adds confidence and 
optimizes success in the prioritization and selection of 
HTS hits for the following chemical optimization phase.
In‑depth characterization of compound binding. The 
advent of sensitive biophysical technologies for time- 
resolved and thermodynamic analysis of protein–ligand 
interactions that do not require reporter groups such as 
enzyme substrates has had a tremendous impact on the 
ability to characterize details of molecular interactions. 
The kinetics of interactions are typically determined by 
SPR biosensor technology and the value of kinetic data 
is well recognized; however, the technology can provide 
additional data for understanding interactions and opti-
mizing lead compounds. Interpretation of the SPR data is 
frequently done assuming a simple one-step reversible 1:1 
interaction model, but exceptions occur and additional 
information can be obtained for some systems. For exam-
ple, interactions between targets and optimized leads 
are often very tight, resulting in essentially irreversible 
dissociation rates that are challenging to quantify owing 
to measurement errors and limited stability of the assay 
system. Qualitative analyses and ranking of compounds 
can still provide useful information for prioritization of 
analogues and further optimization63. Another example is 
dynamic proteins and protein–protein interactions whose 
function and regulation is dependent on complex inter-
action mechanisms involving conformational changes of 
free or bound protein (for example, see Geitmann et al.64 
and Seeger et al.65, respectively). In particular, the deter-
mination of kinetic parameters requires the use of appro-
priate mathematical models that take all parameters and 
the potential mechanism of binding into consideration.
Qualitative details of interactions can also be obtained 
by analysis under different conditions, termed chemody-
namic analysis. Chemodynamic analysis involves a series 
of identical experiments that only differ in buffer pH, 
ionic strength or the presence of other substances that 
influence the interaction. This is valuable information 
as it provides an improved understanding of the domi-
nating interaction forces, which is important for struc-
tural optimization of leads. It also provides a measure of 
the robustness of the interaction throughout different 
experi mental conditions as well as the relevance of the 
data for cellular and in vivo experiments.
In addition, Eyring analysis of the variation of kinetic 
rate constants (for example, from SPR) with temperature 
allows the entropy and enthalpy of the transition state for 
binding to be explored, supplementing the information on 
entropy and enthalpy of binding that can be determined 
from calorimetry. Although it is difficult to predict these 
thermodynamic parameters with computational methods, 
the changes that occur during compound optimization 
can sometimes be rationalized and provide insight into 
the key features required for high-affinity binding.
Assisting lead optimization. In late-stage hit-to-lead or 
lead optimization, the focus of drug discovery projects 
typically moves away from binding affinity and selectivity 
optimization to include a multitude of additional optimi-
zation parameters. These include cellular activity, in vitro 
drug metabolism and pharmacokinetic (DMPK) prop-
erties, physicochemical properties, in vivo pharmaco-
kinetics and efficacy in disease-relevant animal models. 
More recently, biophysical parameters have been used as 
additional optimization criteria. For instance, tailoring 
the residence time of a compound by extending the disso-
ciation rates has been reported to be a useful complement 
to affinity optimization and is in some cases the most 
important parameter4. In some projects, the potency 
of very active compounds is prohibitive for accurate 
quantification of binding in biochemical assays, whereas 
biophysical assays are still able to measure activities in 
the pM range. For in vivo experiments with inconclusive 
pharmacokinetic–pharmacodynamic (PK–PD) relation-
ships, knowledge of the drug residence time on the target 
derived from SPR may be extremely helpful to explain 
the observed data.
BOX 2 shows examples of the successful use of bio-
physics in drug discovery for different purposes: hit 
identification, hit-to-lead optimization, improvement 
of absorption, distribution, metabolism and excretion 
(ADME) properties, attainment of longer residence times 
and identification of allosteric inhibitors.
Emerging technologies and wider applications
TABLE 2 highlights a selection of emerging biophysical 
techniques used in drug discovery. These emerging tech-
niques can either provide new information (for exam-
ple, conformational changes) or the same information 
(kon, koff, Kd and stoichiometry) in a way that is faster or 
simpler than established techniques. Many of these tech-
niques use completely new types of physical principles 
for detection. In addition to the advantages related to the 
information they can provide, crucial factors for their 
establishment include material requirements, ease of use 
and implementation in current drug discovery settings, 
and cost.
Enabling drug discovery for challenging targets. 
Numerous targets prove difficult in small-molecule 
drug discovery, including protein–protein interactions, 
multi-protein complexes and intrinsically disordered 
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Box 2 | Examples of the successful use of biophysical techniques in drug discovery
Biophysical techniques can be used for various purposes in the drug 
discovery process, including (among others): hit identification; hit-to-lead 
optimization; improvement of absorption, distribution, metabolism and 
excretion (ADME) properties; attainment of longer residence times;  
and identification of allosteric inhibitors.
Protein‑observed nuclear magnetic resonance for hit identification. 
Fragment screening can identify hits for targets for which 
high-throughput screening fails. For B cell lymphoma XL (BCL-XL), when 
heteronuclear single quantum coherence (HSQC) measurements can 
detect when ligands bind to the 15N-labelled protein, the structure by 
NMR (or crystallography) can determine binding mode, enabling 
subsequent optimization of the compounds137. Two fragments binding at 
distinct sites (shown in the left-hand side of panel a in the figure; Protein 
Data Bank identifier (PDB ID): 1YSG) provided the basis to develop 
compound 1 with an increased affinity to BCL-XL (shown in the 
right-hand side in panel a; PDB ID: 1YSI). Further optimization led to 
ABT-737. Another high-profile example is the discovery of KRAS 
inhibitors69–71.
Improving ADME properties from crystal structures of compounds bound 
to off‑target proteins. The BCL-XL affinity of compound 1 was strongly 
attenuated in the presence of albumin. In order to identify substituents 
on compound 1 that reduce binding to albumin without affecting affinity 
for BCL-XL, the NMR structure of a thioethylamino-2,4-dimethylphenyl 
analogue of compound 1 (PDB ID: 1YSX) bound to albumin was 
determined. The structure was used to guide the optimization (that is, 
reduction) of plasma protein binding for the BCL-2 and/or BCL-XL 
inhibitor ABT-737 (REF. 137), which was subsequently optimized to the 
recently approved BCL-2-selective inhibitor ABT-199 (venetoclax)66.
Kinetics to identify lead compounds with a long residence time. One step 
in the lead optimization of a chemical series inhibiting the molecular 
chaperone heat-shock protein 90 (HSP90) made a change in the core 
from a pyrazole to an isoxazole138. This gave a large decrease in the 
off-rate for compound binding that was preserved in the isoxazole 
clinical candidate AUY922, and this was reflected in the very long 
residence time on the target.
Off‑rate screening for hit‑to‑lead optimization. A decrease in the off-rate 
(koff) is usually the main contributor to the increase in affinity during 
compound optimization. This rate constant is concentration independent, 
which means that improvements in affinity can be monitored without 
quantification of compounds, provided that the optimized compound 
dominates the interaction. This enables rapid and efficient exploration of 
parallel libraries139. The example shown in panel b of the figure is from a 
retrospective study demonstrating the potential of the method for a series 
of HSP90 inhibitors140. A set of benzene substituents were introduced on to 
the thienopyrimidine fragment by a Suzuki reaction performed in a 96-well 
plate and the resulting reaction mixtures were profiled by surface plasmon 
resonance (SPR). The initial fragment showed a koff of more than 1 s
−1; koff was 
slower for some of the substitution patterns, most strikingly in the 
o,p-dichloro variant (for which it was 0.02 s−1). The koff shown by the crude 
reaction mixture is essentially identical to that of the purified product. 
Off-rate screening dramatically reduces the time needed to profile 
compounds and the amount of material (and solvents) used.
Protein NMR to identify allosteric inhibitors. GNF-2 is a highly selective 
non-ATP-competitive inhibitor of oncogenic BCR–ABL activity. HSQC 
chemical-shift measurements showed that this compound binds to the 
myristate binding site of BCR–ABL rather than the ATP-binding site, which 
is the target of inhibitors such as imatinib. The elucidation of the mode of 
action revealed that the myristate-binding pocket functions as an allosteric 
inhibitor site and that small-molecule starting points for inhibitors at this 
site, such as GNF-2, can be found51. Subsequent X-ray crystallography 
studies and mutational studies were also used during the optimization of 
GNF-2 to give analogues with improved pharmacokinetic properties 
suitable for in vivo studies51. A similar approach has identified allosteric 
inhibitors of farnesyl pyrophosphate synthase141.
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proteins. In particular, protein–protein interactions rep-
resent a highly challenging area. The binding sites are 
large and shallow, with binding hotspots separated by 
long distances. Further challenges include protein con-
formational flexibility and competition with the endog-
enous ligand for the binding site. Biochemical assays 
as used in HTS are frequently not successful in detect-
ing weakly binding compounds that could provide a 
starting point for a medicinal chemistry programme. 
In such cases, biophysical methods are instrumental in 
providing essential ligand binding information. FBDD 
has made some progress for this class of target, with the 
selective B cell lymphoma 2 (BCL-2) inhibitor veneto-
clax (also known as ABT-199)66 being approved by the 
US Food and Drug Administration (FDA) in April 
2016 and clinical candidates identified for other targets 
(for example, hepatitis C virus nonstructural protein 3 
(HCV NS3))67. In addition, early inhibitors have been 
identified for the first time for another member of the 
BCL-2 family, induced myeloid leukaemia cell differ-
entiation protein MCL-1 (REF. 68) and for one of the 
most highly validated (but challenging) drug targets in 
cancer, KRAS69–71. NMR was used to identify fragment 
hits in most of these examples, exploiting the ability 
of this technique to robustly identify weak binding 
compounds. Small-molecule microarray SPR18,19 has 
enabled some hits to be identified for protein–protein 
interactions (by differential screening against the iso-
lated partners and the protein–protein complex) and 
for intrinsically disordered proteins, such as the Tau 
protein72.
Evaluation of target engagement in complex systems. 
Lack of target engagement at the in vivo site of action is 
believed to be a substantial source of attrition in phase II 
proof-of-concept studies73. This emphasizes the need 
for novel technologies to assess target engagement in 
more complex cellular and in vivo systems, preclini-
cally as well as in clinical studies, so that the best com-
pounds are chosen and optimized and more reductionist 
approaches can be validated at an early stage to avoid 
wasted resources.
The recently reported cellular thermal shift assay 
(CETSA) is one of a few currently available biophysical 
methods for this purpose74. Although its strengths and 
weaknesses have not been fully elucidated, the possibility 
to apply the technology directly in live unmodified cells 
and with unmodified compounds within ex vivo tissue 
is tantalizing. In a typical CETSA experiment, vehicle- 
and ligand-treated live cells are heated to different tem-
peratures and the remaining soluble target protein is 
quantified by affinity reagents; for example, Western 
gels or quantitative MS technologies75,76. In its simplest 
interpretation, ligand-induced thermal stabilization 
indicates permeability to a relevant cellular compart-
ment and target binding. Coupling CETSA to a quan-
titative MS proteomic analysis is a recent development, 
and the fingerprint of protein changes highlights both 
the power and complexity of the method, as proteins 
can be destabilized as well as stabilized, and there can be 
pathway-dependent as well as direct effects. Nonetheless, 
CETSA has already demonstrated insights within more 
physiological systems, especially for selectivity profiling 
and target identification studies77.
Study of membrane proteins in a more native‑like 
environment. Studying membrane proteins by bio-
physical techniques is challenging. This is mainly due 
to low gene expression, the low overall yield of protein 
after purification, the typically poor protein stability 
and the need to work with detergents and lipids. More 
than 10 years ago, the application of SPR to detergent- 
solubilized membrane proteins was demonstrated 
on two chemokine receptors, C-C chemokine 
receptor 5 (CCR5) and C-X-C chemokine recep-
tor 4 (CXCR4)78,79. Both receptors were solubilized 
directly from cells with a mixture containing deter-
gents and lipids, and captured on a SPR sensor 
using a specific antibody without prior purification. 
Further studies on isolated membrane receptors 
included fragment-screening applications on wild-
type β2-adrenergic receptor that was solubilized and 
purified in detergent micelles, and finally immobi-
lized with a carboxy-terminal polyhistidine-tag80. 
Furthermore, specific antibodies targeting fusion pro-
teins or tags have enabled biophysical analysis of G 
protein-coupled receptors (GPCRs)81.
Most current studies on purified GPCRs use sta-
bilized variants of receptors, and substantial progress 
in biophysical screening (SPR and target-immobilized 
NMR screening (TINS)) has been demonstrated by 
Heptares82,83 and ZoBio84. After careful assessment 
of ligand binding properties compared to wild-type 
protein, the engineered receptors can be used in bio-
physical studies. Examples include SPR screening of low- 
molecular-mass ligands for stabilized β1-adrenergic and 
adenosine A2A receptors that were captured by a poly-
histidine tag (His-tag) on the sensor surface. Recently, 
the discovery of dual inhibitors for orexin receptors 
(OX1 and OX2) was reported85. To date, stabilized 
GPCRs applied in SPR-based fragment screening have 
been developed by iterative single-point mutagenesis 
and alanine scanning. Directed molecular evolution 
represents an alternative approach to stabilize mem-
brane proteins, as shown with the neurotensin 1 recep-
tor86 (M.H. and S. Huber, unpublished observations). 
This receptor was used for a fragment screening effort 
with 6,369 compounds by SPR followed by hit valida-
tion by NMR, resulting in 4 confirmed hits. This exam-
ple represents the first successful fragment screening 
for a GPCR with a peptidic endogenous ligand (M.H. 
and S. Huber, unpublished observations). The abil-
ity of NMR to detect target–ligand interactions from 
nanomolar to millimolar affinity with high sensitivity 
is a fundamental advantage for membrane proteins. For 
the screening of larger libraries, the TINS approach has 
been successfully applied to wild-type and stabilized 
membrane GPCRs87,88.
Recently, lipid bilayer nanodiscs were developed to 
enable detergent-free membrane protein preparation. 
For example, stabilized human A2A receptor with a com-
bination of affinity tag and green fluorescent protein 
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was used for SPR measurements to characterize small- 
molecule binding in a more native-like environment89. 
Although the off-rates measured this way are similar to 
koff values derived from detergent-solubilized receptors, 
one order of magnitude faster on-rates lead to lower 
observed Kd values. The substantially increased stability 
of the nanodisc sample holds great promise regarding the 
efficient use of less-stabilized receptors for biophysical 
methods.
Besides GPCRs, SPR methods have been developed 
to characterize ligand binding to ion channels, and 
binding affinity as well as binding kinetics were inves-
tigated for, for example, acid-sensing ion channel 1a90, 
γ-aminobutyric acid type A91, 5-hydroxytryptamine 
(5-HT3) 92 and nicotinic receptors93.
ITC measurements with membrane proteins are 
challenging because of the special care required for 
handling of detergents in measurements and analysis 
of the samples. Reports are limited to monotopic mem-
brane proteins such as carnitine palmitoyltransferase 2 
and high-affinity small-molecule characterization in the 
lead-optimization phase94.
Single‑molecule studies. Single-molecule measure-
ments make use of a diverse range of optical analysis 
methods, ranging from atomic force microscopy to 
various optical microscopies with a broad spectrum 
of light combined with ultra-high-resolution imaging 
techniques95–97. With the invention of novel fluorescent 
methods in combination with near-field microscopes 
in the mid-1990s, the application of single-molecule 
techniques to probe properties at the molecular level 
started to increase96–99. Single-molecule methods rep-
resent a potential option for identifying rare as well as 
transient structural states of a protein target or meas-
uring quantitative kinetic parameters, or monitoring 
protein dynamics over time trajectories from seconds 
to minutes while consuming only small amounts of 
sample material.
One advantage of single-molecule methods is the 
low sample consumption, as probe volumes only require 
a femtolitre amount of sample with picomolar protein 
concentrations. Despite several limitations (such as the 
long data collection time, high background to noise 
level and difficulties in analysing low-affinity com-
pounds), the popularity of single-molecule spectros-
copy has increased in the past 10–20 years, especially 
in combination with Förster resonance energy transfer 
(FRET) to study the complex conformational landscape 
of proteins, including the determination of kinetic 
parameters in each conformational state97,100.
Although the well-known single-molecule patch 
clamp technique has been used in drug discov-
ery since the 1970s, the application of other single- 
molecule experiments in drug discovery is scarce owing 
to the complexity of experiments and the limitations 
of the methods101. Further developments — including 
higher-throughput detection on microfluidic chips102, 
Table 2 | Selection of emerging biophysical techniques used in drug discovery
Name Type What is measured? Derived data Refs
Biolayer 
interferometry
Glass fibre‑based 
biosensor
Interaction between white light sent down a glass fibre and 
the light reflected back up to the instrument. The reflected 
light comes from interfaces represented by a sensor surface 
exposed to an analyte and a reference surface with a proprietary 
bio‑compatible layer
Kd, kon and koff 146–148
Backscattering 
interferometry
Microscale 
interferometry of 
HeNe laser light 
and CCD array 
detection
Change in specific refractive index signature of target and ligand 
measured as the mean polarizability of the sample as probed in a 
microfluidic channel
Kd 149,150
Surface acoustic 
wave
Surface‑based 
fluidic biosensor
Real‑time detection of binding‑induced conformational changes 
through monitoring the shift in the phase of surface acoustic 
waves that travel along the biosensor
Conformational 
changes, stoichiometry, 
Kd, kon and koff
33,151, 
152
Second‑harmonic 
generation
Optical prism 
microplate‑based 
biosensor
Proteins labelled with a second‑harmonic‑generation active dye 
are tethered to supported lipid bilayers by a His‑tag. An incident 
femtosecond laser light creates an evanescent wave through 
total internal reflection when it strikes the sensor surface. 
Conformational changes that alter the orientational distribution 
of the label in space or time result in a signal change
Conformational 
changes
153–155
Waveguide‑based 
grating‑coupled 
interferometry
Integrated 
microfluidic surface 
biosensor
Changes in total mass on the biosensor result in a shift of the 
wave’s phase; this phase shift provides information about the on 
and off rates, as well as the stoichiometry of the interaction
Kd, kon and koff 156,157
Electrically 
switchable 
nanolevers
Surface 
microelectrode 
biosensor
Change in amplitude of the mobility of DNA nanolevers 
immobilized on electro‑switchable surface and electrically 
actuated at high frequency. A change in flexibility of molecules 
immobilized to DNA nanolevers alters the wave’s amplitude; 
this directly reflects changes in the conformation of the 
molecules — for example, after binding to compounds
Conformational 
changes, protein size, 
Kd, kon and koff
158
CCD, charge‑coupled device; His‑tag, polyhistidine tag; Kd, dissociation constant; koff, dissociation rate constant; kon, association rate constant.
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progress in fluorophore chemistry, and technical 
improvement of instrumentation, software for data 
collection and analysis — are still needed to enable 
wider application of single-molecule technologies in an 
industrial environment.
Trends in structure‑determination technologies. 
Knowledge about the 3D structures of biomolecules of 
pharmaceutical relevance and their drug complexes has 
proven to be of great value for an efficient and successful 
drug discovery effort. Structural biology provides a 
detailed view on the mode of binding of functionally 
active ligands and enables their structure-guided opti-
mization. The generation of structural information in 
drug discovery has been dominated by X-ray crystallog-
raphy. In contrast to NMR-based methods, there is no 
target size limitation, and the determination of multiple 
structures of target–ligand complexes (an essential step 
for probing the protein-binding pharmacophore with 
structurally distinct ligands) is easily facilitated by either 
co-crystallization or soaking protocols.
Serial femtosecond crystallography (SFX) using ultra-
short pulses of coherent and extremely intense radiation 
generated by X-ray free electron lasers (XFELs) 103,104 and 
high-resolution single-particle cryo electron microscopy 
(cryo-EM)105,106 are two new promising technologies in 
structural biology. With XFELs, it is now possible to 
obtain structural information for notoriously difficult 
targets for which either only very small crystals can be 
obtained (which are not suitable for diffraction experi-
ments on regular synchrotron beamlines) or radiation 
damage is a serious problem (for example, see Kern 
et al.107). In the context of drug discovery, the enhanced 
access to novel structures through SFX — in particu-
lar, structures of challenging membrane protein targets 
— is of great value. SFX does not require work at cryo-
genic temperatures, which helps to derive information 
on molecular dynamics. Furthermore, SFX enables full 
automation of sample handling from crystallization to 
X-ray data collection, as no manual crystal manipulation 
is required. The use of this method in high-throughput 
ligand–complex crystallography will need further tech-
nological developments. Currently, the high level of 
effort involved in determining a structure and the rela-
tively poor data quality limit applications to non-routine, 
low-throughput and high-value projects. 
Cryo-EM is used to study large macromolecular 
complexes (~200–4,000 kDa). Some of these complexes 
reside in membranes, can adopt multiple conforma-
tional states and/or have been refractive to crystalliza-
tion105. Recent examples of targets studied by cryo-EM 
include transient receptor potential cation channel 
subfamily V member 1 (TRPV1)108, γ-secretase109 and 
β-galactosidase, for which a 2.2 Å-resolution structure 
was obtained110. For some systems, cryo-EM is able to 
achieve the resolution needed to elucidate details of pro-
tein–ligand interactions, thus enabling structure-based 
design. Today, the minimal molecular size for high- 
resolution cryo-EM is about 200 kDa106,111, leaving a 
large set of relevant drug targets out of scope. This lim-
itation can probably be reduced by future developments 
in methodology and instrumentation or by studying 
molecular targets in the context of larger, functional 
protein complexes.
Lessons learned and perspectives
The fundamental science of molecular recognition 
and computational methods for data interpretation 
have evolved in parallel with the implementation of 
bio physical methods for drug discovery. The ability to 
accurately determine kinetic rate constants and ther-
modynamic parameters for protein–ligand interactions 
provides the possibility of new insights. For example, for 
inhibitors of HIV1 protease, it was demonstrated that 
kon and koff change from one generation of inhibitors to 
the next. In fact, the fully optimized, latest-generation 
drug molecules have a particularly long residence time112. 
Furthermore, the widespread assumption that similar lig-
ands have similar association rates was clearly not valid, 
as small differences in compound structures have a large 
effect on binding kinetics. Another example is the con-
firmation that the tight binding of ligands containing 
moieties such as hydroxamates and sulfonamides is dom-
inated by the interaction with metal ions (for example, 
Zn2+ ions), and the modulating effects of the other parts 
of the molecule on the kinetics and affinities are not very 
significant113,114. It may thus be difficult to achieve high 
selectivity with compounds that include such moieties.
As with any in vitro assay, it is important to carefully 
explore how the experimental conditions could lead to 
false-positive and false-negative results. Ad hoc selection 
of pH, ionic strength or type of buffer driven by conven-
ience or preliminary protein handling considerations 
needs to be replaced by more attention to the detailed 
physiological conditions for the protein of interest. 
Questions such as ‘what is the tissue location of the active 
drug target?’ or ‘what are the conditions in a particular 
cellular compartment?’ need to be considered before the 
study, and an informed decision made for the selection 
of the experimental conditions to improve the transla-
tion of the results to cellular and in vivo assays. As an 
example, a pH shift of two units for the aspartic protease 
β-secretase 1 (BACE1) substantially reduced the binding 
of all ligands from some chemotypes with micromolar 
affinity at physiological pH (W. Huber, personal com-
munication). The pH dependency of inhibitor interac-
tions with BACE1 has been demonstrated to be a unique 
characteristic of the compounds, influenced not only by 
the active site aspartic residues, but also by changes in the 
ligand’s pKa upon binding115,116. The implications for drug 
design and translation of in vitro data to in vivo effects 
also requires the development of modelling methods117.
Use of kinetic and thermodynamic data: expectations 
and realization. Expectations were raised during the 
past decade that the application of binding kinetics and 
thermodynamics in the selection and optimization of 
leads would improve the success rate of preclinical drug 
discovery. After the pioneering publication of Copeland 
et al.5 in 2006, suggesting a correlation of drug–target 
residence time with drug efficacy and safety, many 
examples have been published in which binding kinetics 
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and residence time were incorporated into the design 
strategies of drug candidates4,118. A popular conclusion 
therefore has been to advocate the use of dissociation 
rates in addition to or instead of affinity as a key param-
eter in compound optimization. However, this approach 
has a number of caveats. First, for many novel targets, the 
desired kinetic drug profile is not known at the outset 
of a drug discovery programme, so it is impossible to 
define a clear goal for off-rate optimization119. Second, 
in the context of drug efficacy, binding kinetics cannot 
be viewed as being independent from pharmacokinetics; 
in fact, in many cases, favourable elimination properties 
of drugs may largely compensate for faster dissociation 
kinetics120. Furthermore, target turnover rates can be 
faster than dissociation rates, such that beneficial effects 
of long residence times will not materialize. Finally, as 
the molecular determinants of binding kinetics are still 
only incompletely understood121, the prospective design 
of kinetic profiles is currently not possible except for 
rare cases, in particular those in which long residence 
times are tuned through a covalent mode of inhibition122. 
Therefore, using binding kinetics in compound optimi-
zation is currently mainly applied in a monitoring mode, 
which, for example, can enable retrospective analyses of 
SKRs or resolve potential cases of PK–PD disconnects.
Similarly, there have been proposals that detailed 
analysis of the contributions from enthalpy and entropy 
to the free energy of binding could aid compound 
selection before lead optimization22,123,124. In these pro-
posals there were simplified assumptions that a large 
negative binding enthalpy is advantageous for target 
selectivity and ADME properties, because it reflects 
predominantly specific, direct and polar interactions 
between the ligand and protein; conversely, a large neg-
ative binding entropy is disadvantageous, because it is 
built mainly on nonspecific van der Waals interactions. 
However, in recent years, wider analysis has demon-
strated that the global parameters ΔH and ΔS: integrate 
multiple contributions of the complex protein–ligand 
binding process (most importantly the dominant role 
of the water structure); are very sensitive to influences 
of the experimental conditions applied in generating the 
experimental data9; and are subject to the phenomenon 
of enthalpy–entropy compensation125. Retrospective 
interpretation of differentiated thermodynamic rep-
ertoires of ligands is only possible with additional 
detailed information at hand — most importantly, high- 
resolution crystal structures of the protein–ligand 
complex containing information on the water network 
within the binding site9,126. Taken together, these factors 
currently preclude the prospective use of thermody-
namics in compound prioritization. Therefore, current 
applications focus on deriving mechanistic information 
on binding modes and protein conformational changes 
when ITC data are used in concert with structural and 
computational analyses127.
Figure 2 | Biophysical techniques in drug discovery: throughput versus content. The typical size of the compound 
collections involved at the different stages of drug discovery decreases from 105–106 for high‑throughput screening (HTS) 
to 103–104 for fragment‑based screening (FBS) and then to 101–102 for the hit‑to‑lead stage followed by lead optimization. 
The throughput of the biophysical techniques used at different stages should be adapted to the size of the corresponding 
compound collections. In general, the information content of the techniques is inversely proportional to their throughput. 
For instance, HTS provides a high to ultra‑high throughput but a low information content (usually just ‘yes or no’ binding 
information). Conversely, lead optimization requires the highest information content to guide the choice of the best 
compounds for the next step (drug candidate selection) and the methods used generally have lower throughput. AS‑MS, 
affinity‑selection mass spectrometry; ITC, isothermal calorimetry; FP, fluorescence polarization; FRET, Förster resonance 
energy transfer; NC‑MS, non‑covalent mass spectrometry; NMR, nuclear magnetic resonance; SPR, surface plasmon 
resonance; TSA, thermal shift analysis.
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Selection of a biophysical method to fit the purpose. The 
choice of a biophysical method will first depend on the 
drug discovery stage — hit generation (HTS or FBS), 
hit-to-lead or lead optimization — in order to find the 
best compromise between the throughput, the size of 
the library to be screened, the sample availability and the 
expected information content (FIG. 2). For instance, ITC 
will clearly not be the best choice for a primary screening, 
but it will bring a wealth of valuable information for com-
pound classification and prioritization at a later stage.
In FBS, different screening methods retrieve dis-
tinct sets of binders49. The choice of which methods to 
use for which targets is based on a number of factors, 
some pertaining to the availability and type of target 
protein. Moreover, skill in the application and choice of 
a method is as important as the method itself. An often 
unrecognized factor is that some biophysical technology 
can be deceptively user-friendly and easily generates 
large amounts of data. However, without skilled exper-
imentalists the data are not meaningful. The reasons for 
this vary, but include inappropriate experimental design 
and conditions, poorly performed experiments, lack 
of suitable controls and incorrect or inadequate data 
analy sis. For example, in SPR biosensor analysis, the 
basic art of fast and accurate pipetting and performing 
appropriate controls is crucial. Moreover, the visualiza-
tion, presentation and interpretation of data also require 
experience. Although there is no excuse for poor quality 
work, each method shows limits and artefacts but, by 
recognizing and addressing them, a suitable combina-
tion of methods can provide the required information.
All in all, the best way to obtain a high rate of val-
uable hits from a screening campaign seems to be to 
use a robust, high-throughput, low-sample-consuming 
technique for primary screening and to confirm hits 
using lower-throughput but higher-content orthogonal 
techniques. Contrary to the belief that all drug discov-
ery challenges are best solved through the introduction 
of new technologies, substantial advances can also be 
driven by innovative application. The kinetic probe 
competition assay (kPCA) for the discovery and char-
acterization of GPCR ligands provides such an exam-
ple of creative experimental design rather than novel 
instrumentation to extend the toolbox of technologies 
to progress drug discovery128,129.
Summary and outlook
The increasing application of biophysical methods, espe-
cially over the past 10 years, has led to an improved pro-
cess for compound prioritization and decision-making 
in early-stage drug discovery, based on valuable addi-
tional experimental information. For conventional sol-
uble target classes, the use of biophysical measurements 
is well established, as the preceding steps of protein 
production and enablement of target-specific assays 
are normally well understood. This enables biophysical 
primary screening, secondary screening and detailed 
characterization assays to be developed on timelines 
that match other screening activities, and thus enables 
their integration into hit identification approaches. One 
major benefit of such integration is the ability to reliably 
and quickly identify true positive hits, thereby reducing 
wasted resources and increasing return on investment.
Furthermore, biophysical methods are crucial to the 
success of FBDD. The delivery of clinical candidates 
for difficult drug targets, such as protein–protein inter-
actions, and an increasing number of marketed drugs 
derived from FBDD are testimony to the integral role it 
now has in drug discovery. Finally, biophysical methods 
are extensively used by medicinal chemists working on the 
challenge of multi-parameter optimization of compounds.
The future holds considerable promise for the exten-
sion of applications of biophysical methods. Improved 
abilities to produce large amounts of high-quality 
proteins, including membrane proteins, will increase 
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research.
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